Abstract
p27Kip1 is a regulator of the mammalian cell cycle and a putative tumor suppressor. Distinct altered patterns of p27Kip1 protein expression are found in a variety of human carcinomas, and p27Kip1 expression levels usually correlate directly with disease-free survival. The mechanism(s) by which p27Kip1 expression is reduced or lost during tumorigenesis remains unclear. Specific alterations of the p27Kip1 gene, including mutations and homozygous deletions, are exceedingly rare in human cancers. We have used methylation-specific PCR and bisulfite genomic sequencing to examine the methylation status of p27Kip1 in 61 primary and metastatic tumors and 35 cell lines from patients with malignant melanoma. Dense methylation of a CpG island in the promoter region of p27Kip1 was detected in four of 45 metastatic tumors (9%) and three of the cell lines (9%), including two cell lines established from two different metastases from the same patient. Examination of a naturally occurring, allele-specific sequence variant demonstrated that p27Kip1 methylation is associated with transcriptional silencing in situ. Cell lines with p27Kip1 methylation showed retention of the wild-type allele and detectable p27Kip1 protein whose abundance was reduced compared with normal melanocytes. Collectively, our data suggest that DNA methylation may be a cause of monoallelic p27Kip1 silencing in malignant melanoma, which would support a role for p27Kip1 haploinsufficiency in human cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bartkova J, Zemanova M and Bartek J. . 1996 Int. J. Cancer 66: 732–737.
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM. . 1997 Nat. Med. 3: 227–220.
Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM and Sherr CJ. . 1999 EMBO J. 18: 1571–1583.
Coats S, Flanagan WM, Nourse J and Roberts JM. . 1996 Science 272: 877–880.
Decker HJ, Li FP, Bixenman HA and Sandberg AA. . 1990 Cancer Genet. Cytogenet. 46: 135–137.
Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A. . 1997 Cancer Res. 57: 3381–3385.
Fero ML, Randel E, Gurley KE, Roberts JM and Kemp CJ. . 1998 Nature 396: 177–180.
Firpo EJ, Koff A, Solomon MJ and Roberts JM. . 1994 Mol. Cell. Biol. 14: 4889–4901.
Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM and Holm R. . 1998 Am. J. Pathol. 153: 305–312.
Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF and Zeuthen J. . 1997 Cancer Res. 57: 3660–3663.
Hatta Y, Takeuchi S, Yokota J and Koeffler HP. . 1997 Br. J. Cancer 75: 1256–1262.
Hengst L and Reed SI. . 1998 Curr. Top. Microbiol. Immunol. 227: 25–41.
Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB. . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826.
Kato JY, Matsuoka M, Polyak K, Massague J and Sherr CJ. . 1994 Cell 79: 487–496.
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J and Wilcynski S. . 1995 Cancer Res. 55: 2266–2269.
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E. . 1997 Genes Dev. 11: 847–862.
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M. . 1997 Nat. Med. 3: 231–234.
Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M and Koeffler HP. . 1995 Blood 86: 1924–1930.
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M. . 1995 Science 269: 682–685.
Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW and Rowley JD. . 1995 Cancer Res. 55: 1206–1210.
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A. . 1994 Genes Dev. 8: 9–22.
Ponce-Castañeda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J and Massague J. . 1995 Cancer Res. 55: 1211–1214.
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM. . 1997 Nat. Med. 3: 222–225.
Sherr CJ and Roberts JM. . 1999 Genes Dev. 13: 1501–1512.
Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW and Koeffler HP. . 1996 Cancer Res. 56: 2400–2404.
Takeuchi S, Mori N, Koike M, Slater J, Park S, Miller CW, Miyoshi I and Koeffler HP. . 1996 Cancer Res. 56: 738–740.
Acknowledgements
We thank Anette Birck and Klaus Hou-Jensen for providing melanoma tissue samples, and Vibeke Ahrenkiel and Tina Seremet for technical assistance. This work was supported by grants from the Danish Cancer Society, the Danish Medical Research Council, the Danish Cancer Research Foundation, the Novo Nordisk Foundation, the Astrid Thaysen Foundation, and the Kaarsen Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Worm, J., Bartkova, J., Kirkin, A. et al. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 19, 5111–5115 (2000). https://doi.org/10.1038/sj.onc.1203891
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203891
Keywords
This article is cited by
-
Promoter hypermethylation of p73 and p53 genes in cervical cancer patients among north Indian population
Molecular Biology Reports (2012)
-
Functional Modulation of IGF-Binding Protein-3 Expression in Melanoma
Journal of Investigative Dermatology (2010)
-
The emerging roles of forkhead box (Fox) proteins in cancer
Nature Reviews Cancer (2007)
-
Rb/E2F: A two-edged sword in the melanocytic system
Cancer and Metastasis Reviews (2005)
-
Loss of heterozygosity at 12p13 and loss of p27KIP1 protein expression contribute to melanoma progression
Virchows Archiv (2004)